



PRESS RELEASE

ASLAN PHARMACEUTICALS TO PARTICIPATE IN THE 35th ANNUAL PIPER SANDLER HEALTHCARE CONFERENCE

San Mateo, California, and Singapore, November 20, 2023 – ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, will participate in a fireside discussion at the Piper Sandler Healthcare Conference. The conference will be held from November 28 to 30, 2023, in-person at the Lotte New York Palace Hotel, in New York.

35TH Annual Piper Sandler Healthcare Conference Participation Information

Format: Fireside discussion

Presenter: Carl Firth, CEO, ASLAN Pharmaceuticals

Date: Wednesday, November 29, 2023

Time: 11:30 AM ET

A replay of the fireside discussion will be made available on the Investor Relations section of ASLAN's [website](#).

Management will also be available for one-on-one meetings with investors during the time of the conference. Please contact your representative at Piper Sandler to schedule a meeting.

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is developing *eblasakimab*, a potential first-in-class antibody targeting the IL-13 receptor in moderate-to-severe atopic dermatitis (AD) with the potential to improve upon current biologics used to treat allergic disease, and has reported positive topline data from a Phase 2b dose-ranging study in moderate-to-severe AD patients. ASLAN is also developing *farudodstat*, a potent oral inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH) as a potential first-in-class treatment for alopecia areata (AA) in a Phase 2a, proof-of-concept trial with an interim readout expected in 1Q 2024. ASLAN has teams in San Mateo, California, and in Singapore. For additional information please visit the [Website](#) or follow ASLAN on [LinkedIn](#).

Ends

Media and IR contacts

Emma Thompson
Spurwing Communications
Tel: +65 6206 7350
Email: ASLAN@spurwingcomms.com

Ashley R. Robinson
LifeSci Advisors, LLC
Tel: +1 (617) 430-7577
Email: arr@lifesciadvisors.com